| |
MESSAGE _ENGLISH VERSION_ |
|
| |
Preclinical in-vivo data for RVU602, a novel ADC payload, presented at
the World ADC Congress 2026
The Management Board of Ryvu Therapeutics S.A. with its registered
office in Kraków _the "Company", "Ryvu"_ announces that on October 14,
2026, the Company presented preclinical data, including in-vivo
proof-of-concept data, on antibody-drug conjugates _ADCs_ based on
RVU602 - its proprietary, potentially first-in-class ADC payload - at
the World ADC Congress 2026, held on October 12-15, 2026, in San Diego,
CA, USA.
Details of the poster presentation:
Poster No. 96: RVU602: A Non-TOPO1/Non-Tubulin Payload for
Next-Generation ADCs
Session date and time: October 14, 2026, 10:00 AM PDT _7:00 PM CEST_
What differentiates the RVU602 payload
- A third mechanistic class. Transcriptomic profiling shows that RVU602
induces neither thereplication-stress signature characteristic of TOPO1
inhibitors nor the mitotic-arrest signature of tubulin inhibitors. This
opens the option of sequencing RVU602-based ADCs after, or combining
them with, DXd- and MMAE-based ADCs.
- Active in TOPO1 inhibitor-resistant tumors. In cells carrying a TOPO1
mutation, deruxtecan _DXd_ lost more than 100-fold potency, whereas
RVU602 retained full activity _resistant/parental EC50 ratio of
1.0-4.4_. This is directly relevant for the growing population of
patients progressing onTOPO1 inhibitor-based ADCs.
- No efflux liability. In a P-gp-high cell line, RVU602 potency was
essentially unaffected by P-gp inhibition _1.6-fold shift, versus
3.7-fold for DXd and 12-fold for MMAE_, indicating that RVU602 overcomes
a major efflux-driven resistance route.
- Built-in immunomodulatory activity. Beyond direct cytotoxicity, RVU602
induces the release ofextracellular ATP, a hallmark of immunogenic cell
death, supporting the potential of RVU602-based ADCs in combination with
immune checkpoint blockade.
- Deep, pan-tumor cytotoxicity. Across a panel of 272 cancer cell lines,
RVU602 showed broad cytotoxic activity and a markedly deeper response
than DXd.
ADC validation and in-vivo proof of concept
- RVU602 was conjugated to four antibodies - sacituzumab _anti-TROP2_,
cetuximab _anti-EGFR_, telisotuzumab _anti-c-MET_ and trastuzumab
_anti-HER2_. The resulting ADCs showed high monomeric content _>95%_,
high drug-to-antibody ratios _DAR 6-8_ and low payload release inplasma
_<1% in mouse and <15% in human plasma after 7 days_.
- RVU602 ADCs combined sub-nanomolar potency with complete tumor cell
killing in-vitro, outperforming datopotamab deruxtecan _Dato-DXd_ and
matching a cetuximab-MMAE comparator.
- In patient-derived TROP2-positive TNBC cells, the RVU602 ADC achieved
low-nanomolar potency _EC50 0.4-7.5 nM_ with 100% efficacy and 30- to
250-fold selectivity over the isotype control, supporting its
translational potential.
- In the TROP2-positive HCC70 TNBC xenograft model, the
sacituzumab-RVU602 ADC led to complete responses in 100% of animals
after two doses at 10 mg/kg once weekly _QW_ and in 83% of animals after
four doses at 5 mg/kg twice weekly _BIW_. Strong target engagement in
tumors correlated with tumor growth inhibition. Sacituzumab govitecan
_20 mg/kg QW_ was included asareferencearm.
Together, these data validate RVU602 across multiple antibody targets
and models, including settings resistant to topoisomerase I inhibitors,
and support RVU602 as a differentiated payload for next-generation ADCs.
The poster will be available on the Ryvu website after the presentation:
https://ryvu.com/investors-media/publications/
|
|
|
RB: Dane przedkliniczne in vivo dla RVU602 - nowej substancji czynnej do ADC - zaprezentowane
podczas World ADC Congress 2026 / Preclinical in-vivo data for RVU602, a novel ADC
payload, presented at the World ADC Congress 2026
